MA37618A1 - Dérivés pontés fluorés de spiro[2.4]heptane en tant qu'agonistes de récepteur alx - Google Patents
Dérivés pontés fluorés de spiro[2.4]heptane en tant qu'agonistes de récepteur alxInfo
- Publication number
- MA37618A1 MA37618A1 MA37618A MA37618A MA37618A1 MA 37618 A1 MA37618 A1 MA 37618A1 MA 37618 A MA37618 A MA 37618A MA 37618 A MA37618 A MA 37618A MA 37618 A1 MA37618 A1 MA 37618A1
- Authority
- MA
- Morocco
- Prior art keywords
- heptane
- fluor
- receptor agonists
- alx receptor
- bridged derivatives
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/14—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
Abstract
La présente invention concerne des dérivés pontés fluorés de spiro[2.4]heptane de formule (i), où n et r
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12168322 | 2012-05-16 | ||
PCT/IB2013/053976 WO2013171694A1 (fr) | 2012-05-16 | 2013-05-15 | Dérivés pontés fluorés de spiro[2.4]heptane en tant qu'agonistes de récepteur alx |
Publications (2)
Publication Number | Publication Date |
---|---|
MA37618A1 true MA37618A1 (fr) | 2016-12-30 |
MA37618B1 MA37618B1 (fr) | 2017-08-31 |
Family
ID=48699893
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA37618A MA37618B1 (fr) | 2012-05-16 | 2013-05-14 | Dérivés pontés fluorés de spiro[2.4]heptane en tant qu'agonistes de récepteur alx |
Country Status (23)
Country | Link |
---|---|
US (1) | US9139524B2 (fr) |
EP (1) | EP2850060B1 (fr) |
JP (1) | JP6101789B2 (fr) |
KR (1) | KR20150013285A (fr) |
CN (1) | CN104321309B (fr) |
AR (1) | AR091059A1 (fr) |
AU (1) | AU2013261091B2 (fr) |
BR (1) | BR112014028358A2 (fr) |
CA (1) | CA2871336A1 (fr) |
CL (1) | CL2014002918A1 (fr) |
EA (1) | EA025264B1 (fr) |
ES (1) | ES2595219T3 (fr) |
HK (1) | HK1208441A1 (fr) |
IL (1) | IL235660A0 (fr) |
MA (1) | MA37618B1 (fr) |
MX (1) | MX355221B (fr) |
NZ (1) | NZ702971A (fr) |
PH (1) | PH12014502465A1 (fr) |
PL (1) | PL2850060T3 (fr) |
SG (1) | SG11201406971WA (fr) |
TW (1) | TWI579269B (fr) |
WO (1) | WO2013171694A1 (fr) |
ZA (1) | ZA201409249B (fr) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2640699B1 (fr) | 2010-11-17 | 2015-10-07 | Actelion Pharmaceuticals Ltd. | Dérivés d'esters de spiro[2.4]heptane pontés |
ES2604135T3 (es) | 2010-12-07 | 2017-03-03 | Actelion Pharmaceuticals Ltd. | Derivados de aminotriazol hidroxilados como agonistas del receptor ALX |
EP2850058B1 (fr) | 2012-05-16 | 2016-07-13 | Actelion Pharmaceuticals Ltd. | Dérivés de 1- (p-tolyl) cyclopropyl substituted bridged spiro [2,4] heptane en tant qu' agonistes du récepteur alx. |
AR096686A1 (es) | 2013-06-25 | 2016-01-27 | Actelion Pharmaceuticals Ltd | Derivados de espiro[2.4]heptano puenteados sustituidos con difluoroetil-oxazol como agonistas del receptor de alx |
AU2014292064B2 (en) | 2013-07-18 | 2018-07-05 | Idorsia Pharmaceuticals Ltd | Piperazine substituted bridged spiro[2.4]heptane derivatives as alx receptor agonists |
AR097279A1 (es) | 2013-08-09 | 2016-03-02 | Actelion Pharmaceuticals Ltd | Derivados de benzimidazolil-metil urea como agonistas del receptor de alx |
CN106459076B (zh) | 2014-05-13 | 2019-01-04 | 诺华股份有限公司 | 用于诱导软骨发生的化合物和组合物 |
EP3331884B1 (fr) | 2015-05-27 | 2020-06-17 | Kyorin Pharmaceutical Co., Ltd. | Dérivé de l'urée ou sel pharmacologiquement acceptable de ce dernier |
EP3303284B1 (fr) | 2015-05-27 | 2020-04-08 | Kyorin Pharmaceutical Co., Ltd. | Dérivé d'urée ou sel pharmacologiquement acceptable de celui-ci |
CN111233751B (zh) * | 2020-03-25 | 2021-02-02 | 丽水绿氟科技有限公司 | 一种3,3-二氟-4-氨基哌啶类化合物及其衍生物的制备方法 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH09500133A (ja) * | 1993-07-16 | 1997-01-07 | メルク エンド カンパニー インコーポレーテッド | オキシトシンのアンタゴニストである置換ピペラジニル樟脳誘導体 |
AU2003214249A1 (en) | 2002-04-03 | 2003-10-13 | Bayer Aktiengesellschaft | Diagnostics and therapeutics for diseases associated with n-formyl peptide receptor like 1 (fprl1) |
JP2007508260A (ja) | 2003-10-09 | 2007-04-05 | アクテリオン ファマシューティカルズ リミテッド | 新規なテトラヒドロピリジン誘導体 |
KR20060130064A (ko) | 2003-11-07 | 2006-12-18 | 아카디아 파마슈티칼스 인코포레이티드 | 통증 및 염증 치료에 효과적인 화합물을 동정하기 위한도구로서의 리폭신 수용체, fprl1의 용도 |
TW200538098A (en) | 2004-03-22 | 2005-12-01 | Astrazeneca Ab | Therapeutic agents |
US7820699B2 (en) | 2005-04-27 | 2010-10-26 | Hoffmann-La Roche Inc. | Cyclic amines |
CN101679422A (zh) | 2007-03-28 | 2010-03-24 | 阵列生物制药公司 | 作为受体酪氨酸激酶抑制剂的咪唑并[1,2-a]吡啶化合物 |
AR069650A1 (es) | 2007-12-14 | 2010-02-10 | Actelion Pharmaceuticals Ltd | Derivados de aminopirazol como agonistas no peptidicos del receptor alx humano |
NZ586735A (en) | 2007-12-18 | 2012-06-29 | Actelion Pharmaceuticals Ltd | Aminotriazole derivatives as alx agonists |
TWI490190B (zh) * | 2009-05-18 | 2015-07-01 | Actelion Pharmaceuticals Ltd | 橋聯螺〔2.4〕庚烷衍生物 |
WO2010143116A1 (fr) | 2009-06-09 | 2010-12-16 | Actelion Pharmaceuticals Ltd | Dérivés fluorés de l'aminotriazole |
CA2760887A1 (fr) | 2009-06-12 | 2010-12-16 | Actelion Pharmaceuticals Ltd | Derives de l'oxazole et du thiazole en tant qu'agonistes du recepteur alx |
CA2803920A1 (fr) | 2010-06-24 | 2011-12-29 | Richard Beard | Derives d'acides cycloalkyl- et cycloalcenyl-1,2-dicarboxyliques presentant une activite agoniste ou antagoniste du recepteur fprl-1 |
EP2640699B1 (fr) | 2010-11-17 | 2015-10-07 | Actelion Pharmaceuticals Ltd. | Dérivés d'esters de spiro[2.4]heptane pontés |
ES2604135T3 (es) | 2010-12-07 | 2017-03-03 | Actelion Pharmaceuticals Ltd. | Derivados de aminotriazol hidroxilados como agonistas del receptor ALX |
MX2013006418A (es) | 2010-12-07 | 2013-07-15 | Actelion Pharmaceuticals Ltd | Derivados de oxazolil-metileter como agonistas del receptor de alx. |
WO2013009543A1 (fr) * | 2011-07-11 | 2013-01-17 | Allergan, Inc. | Dérivés polycycliques de pyrrolidine-2,5-dione en tant que modulateurs du récepteur fprl-1 (récepteur de n-formyl peptide de type 1) |
EP2850058B1 (fr) | 2012-05-16 | 2016-07-13 | Actelion Pharmaceuticals Ltd. | Dérivés de 1- (p-tolyl) cyclopropyl substituted bridged spiro [2,4] heptane en tant qu' agonistes du récepteur alx. |
KR20210024691A (ko) | 2013-03-06 | 2021-03-05 | 알러간, 인코포레이티드 | 피부 질환 치료용 포르밀 펩티드 수용체 2의 항진제의 용도 |
JP6196327B2 (ja) | 2013-03-06 | 2017-09-13 | アラーガン、インコーポレイテッドAllergan,Incorporated | 眼炎症性疾患の治療のためのホルミルペプチド受容体2のアゴニストの使用 |
-
2013
- 2013-05-14 MA MA37618A patent/MA37618B1/fr unknown
- 2013-05-15 NZ NZ702971A patent/NZ702971A/en not_active IP Right Cessation
- 2013-05-15 BR BR112014028358-3A patent/BR112014028358A2/pt not_active IP Right Cessation
- 2013-05-15 EA EA201401259A patent/EA025264B1/ru not_active IP Right Cessation
- 2013-05-15 JP JP2015512184A patent/JP6101789B2/ja not_active Expired - Fee Related
- 2013-05-15 PL PL13731938T patent/PL2850060T3/pl unknown
- 2013-05-15 MX MX2014013829A patent/MX355221B/es active IP Right Grant
- 2013-05-15 AR ARP130101686 patent/AR091059A1/es unknown
- 2013-05-15 WO PCT/IB2013/053976 patent/WO2013171694A1/fr active Application Filing
- 2013-05-15 SG SG11201406971WA patent/SG11201406971WA/en unknown
- 2013-05-15 CN CN201380025040.5A patent/CN104321309B/zh not_active Expired - Fee Related
- 2013-05-15 AU AU2013261091A patent/AU2013261091B2/en not_active Ceased
- 2013-05-15 TW TW102117256A patent/TWI579269B/zh not_active IP Right Cessation
- 2013-05-15 US US14/401,769 patent/US9139524B2/en not_active Expired - Fee Related
- 2013-05-15 EP EP13731938.0A patent/EP2850060B1/fr not_active Not-in-force
- 2013-05-15 ES ES13731938.0T patent/ES2595219T3/es active Active
- 2013-05-15 KR KR20147034766A patent/KR20150013285A/ko not_active Application Discontinuation
- 2013-05-15 CA CA2871336A patent/CA2871336A1/fr not_active Abandoned
-
2014
- 2014-10-28 CL CL2014002918A patent/CL2014002918A1/es unknown
- 2014-11-05 PH PH12014502465A patent/PH12014502465A1/en unknown
- 2014-11-12 IL IL235660A patent/IL235660A0/en unknown
- 2014-12-15 ZA ZA2014/09249A patent/ZA201409249B/en unknown
-
2015
- 2015-09-14 HK HK15108959.5A patent/HK1208441A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
ZA201409249B (en) | 2016-09-28 |
KR20150013285A (ko) | 2015-02-04 |
CA2871336A1 (fr) | 2013-11-21 |
JP2015516463A (ja) | 2015-06-11 |
AU2013261091B2 (en) | 2017-04-06 |
SG11201406971WA (en) | 2014-11-27 |
IL235660A0 (en) | 2015-02-01 |
WO2013171694A1 (fr) | 2013-11-21 |
CN104321309B (zh) | 2016-06-22 |
CL2014002918A1 (es) | 2015-02-06 |
EP2850060B1 (fr) | 2016-07-13 |
EA201401259A1 (ru) | 2015-04-30 |
EA025264B1 (ru) | 2016-12-30 |
AR091059A1 (es) | 2014-12-30 |
TW201348198A (zh) | 2013-12-01 |
MA37618B1 (fr) | 2017-08-31 |
NZ702971A (en) | 2016-09-30 |
PH12014502465A1 (en) | 2014-12-22 |
MX2014013829A (es) | 2015-02-04 |
EP2850060A1 (fr) | 2015-03-25 |
CN104321309A (zh) | 2015-01-28 |
JP6101789B2 (ja) | 2017-03-22 |
BR112014028358A2 (pt) | 2020-07-21 |
PL2850060T3 (pl) | 2017-01-31 |
US20150118258A1 (en) | 2015-04-30 |
US9139524B2 (en) | 2015-09-22 |
ES2595219T3 (es) | 2016-12-28 |
HK1208441A1 (en) | 2016-03-04 |
AU2013261091A1 (en) | 2015-01-22 |
TWI579269B (zh) | 2017-04-21 |
MX355221B (es) | 2018-04-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA37618A1 (fr) | Dérivés pontés fluorés de spiro[2.4]heptane en tant qu'agonistes de récepteur alx | |
MA35905B1 (fr) | Composés de bêta-lactame à substitution amidine, leur préparation et leur utilisation en tant qu'agents antibactériens | |
MA37940A2 (fr) | Nouveaux dérivés bicycliques | |
MA35664B1 (fr) | Nouveaux dérivés bicycliques de la dihydroisoquinoline-1-one | |
CR20150296A (es) | Novedosos derivados de bencimidazol como antagonistas de ep4 | |
MA35096B1 (fr) | Cyclopropylamines en tant qu'inhibiteurs de lsd1 | |
MA35357B1 (fr) | Composes de type anilines | |
EA201490912A1 (ru) | Производные [1,2,3]триазоло[4,5-d]пиримидина в качестве агонистов каннабиноидного рецептора 2 | |
MA39172A1 (fr) | Dérivés bicycliques hétérocycliques comme inhibiteurs de bromodomaines | |
MA35089B1 (fr) | Inhibiteurs de la production de leucotrienes de type benzodioxane | |
MA34078B1 (fr) | Derives d'arylethynyle | |
EA201591008A1 (ru) | Пиридин-2-амиды, пригодные в качестве агонистов каннабиноидного рецептора 2 | |
MA38239A1 (fr) | Nouveaux dérivés de pyridine | |
MA35663B1 (fr) | Dérivés de [1, 2, 3]triazolo [4, 5 -d] pyrimidine comme agonistes des récepteurs aux cannabinoïdes 2 | |
MA38112B1 (fr) | Dérivés d'imidazopyridazine en tant que modulateurs d'un récepteur gabaa | |
MA38460B1 (fr) | Dérivés de la purine en tant qu'agonistes du récepteur cb2 | |
MA38555B1 (fr) | Dérivés de pyrrolo[2,3-d]pyrimidine en tant qu'agonistes du récepteur cb2 | |
FR3064634B1 (fr) | Derives acryliques de 1 :4, 3 :6 dianhydrohexitol | |
MA38679B1 (fr) | Modulateurs du récepteur de cxcr7 | |
IN2014DN05972A (fr) | ||
MA35742B1 (fr) | Dérivés de n- (4 -quinolinylmethyl) sulfonamide et leur utilisation en tant qu'antihelminthiques | |
MX360699B (es) | Derivados de espiro [2.4] heptano puenteado substituidos por piperazina, utilizados como agonistas del receptor alx. | |
MX2015017541A (es) | Derivados de espiro [2.4] heptano puenteados sustituidos con difluoroetil-oxazol como agonistas del receptor de alx. | |
MA38010B1 (fr) | Dérivés d'éthynyl utilisés en tant que modulateurs de l'activité des récepteurs mglur5 | |
MA37999B1 (fr) | Dérivés de macrolide, leur préparation et leur utilisation thérapeutique |